Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

THOUSAND OAKS, Calif., Sept. 8, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced results from two analyses of the Phase 2 CodeBreaK 100 clinical trial evaluating LUMAKRAS™ (sotorasib), the first and only KRASG12C inhibitor approved in the U.S., in the treatment of previously treated patients with advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC).

Amgen Presents New Data From Thoracic Oncology Portfolio At WCLC21

Alibaba

Dollar Tree

Looking for a deal? Don't overlook these stocks.

3 Beaten-Up Stocks for Bargain Hunters

Bristol-Myers

Enterprise Products Partners

Merck

Pembina Pipeline

Reinsurance Group of America

Unum

In this article, we're looking at the companies I consider the most investable for September of 2021. I look for investment-graded dividend-paying stocks with a conservative RoR of no less than 15% over a 3-4-year period.

Undervalued Dividend Stocks For September With 10-20% Upside

THOUSAND OAKS, Calif., Sept. 5, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the pivotal NAVIGATOR Phase 3 trial demonstrating that tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps.1 Tezepelumab is a potential first-in-class treatment that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin (TSLP), an epithelial cytokine, and has the potential to treat a broad population of patients with severe asthma.2,3 Tezepelumab is being developed by Amgen in collaboration with AstraZeneca.

New Tezepelumab Data Show 86% Reduction In Exacerbations In Patients With Severe Asthma And Comorbid Nasal Polyps

THOUSAND OAKS, Calif., Sept. 3, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 16th Annual BioPharma Conference at 1:25 p.m.

Amgen to Present at the 16th Annual Citi BioPharma Conference

Broadcom

Bank of Montreal

Clorox

Darden Restaurants

Evergy Inc

General Mills

Kellogg

Kimberly-Clark

Lockheed Martin

M&T Bank

PepsiCo

Principal Financial Group

Philip Morris

Restaurant Brands

Rogers Communications

Royal Bank of Canada

Southern Company

Sempra Energy

Toronto-Dominion Bank

Truist Financial

WEC Energy Group

There are 23 High-Yield Dividend Stocks on the September 2021 watchlist. The watchlist gained 1.81% in August and is up over 40% since November 2020.

High Yield Dividend Stocks For September 2021

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?

Amgen (AMGN) Down 2.2% Since Last Earnings Report: Can It Rebound?

Home Depot

Intel

Texas Instruments

Home Depot, Intel, and PepsiCo are among the stocks identified as having low ESG risk, yields of at least 2%, and large market caps.

Here's How to Marry ESG and Dividends. And 5 Picks for a Start.

Boeing

Visa

Pullbacks have translated into lower prices, but not every lower-priced name is worth purchasing just yet.

Is It Time to Buy the Dow Jones' 3 Worst-Performing Stocks in August?

Cardinal Health

SPDR Dow Jones Industrial Average ETF

Henkel AG & Co KGaA

Invesco QQQ

SPDR S&P 500 ETF Trust

Tencent Holdings Limited

While the stock market seems extremely expensive, it is still a market of stocks enabling us to find some good picks. Four sleep-well stocks might be the two consumer goods companies Reckitt Benckiser and Henkel as well as the two healthcare companies Cardinal Health and Amgen.

Remember, Remember To Come Back In September: 6 Stock Picks

Amgen continues to face the headwind of patient visits that are lower than before the pandemic.

Does the Pullback in This Pharma Stock Create a Buying Opportunity?

Amgen Inc (NASDAQ: AMGN) has announced positive data from the HUYGENS Phase 3 study assessing if Repatha (evolocumab) could increase the thickness of the fibrous caps to improve a feature of plaque stability. The data were presented at the oral presentation at ESC Congress 2021.

Amgen's Repatha Improves Plaque Stability In Heart Patients

THOUSAND OAKS, Calif., Aug. 27, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive data from the HUYGENS Phase 3 study showing that Repatha® (evolocumab) in addition to optimized statin therapy, in comparison with optimized statin therapy alone, significantly improved features of plaque stability in patients with coronary artery disease (CAD).

New Data At ESC Congress 2021 Shows Repatha® (evolocumab) Improves Features Of Plaque Stability In Patients With Acute Coronary Syndrome (ACS)

Amgen Inc. ( AMGN , Financial) reported quarterly results at the beginning of August that came in ahead of Wall Street analysts' estimates and showed improvement against the prior year. Yet, shares have decreased more than 8% since then, even as the S&P 500 index has grinded higher by 1.5%.

Amgen Represents Good Value Following Sell-Off

Amgen is now solidly in value territory after the material share price drop over the past month.

Amgen: Here's Why It Is An Excellent Value Buy Right Now

The market is now selling off after one of the best years in history but remains 28% overvalued.

3 Reasons I Own Amgen In My Retirement Portfolio And So Should You

Amgen is yielding over 3% and has raised the dividend for 10 years in a row making the stock a Dividend Contender. The company is facing competitive pressures and higher costs.

Amgen: Strong Pipeline Makes It A Buy

Amgen reported solid second quarter results. Although Amgen is clearly facing some risks, I think analysts are way too cautious about the company's growth potential.

Amgen Is Undervalued By At Least 20%

Amgen is a relatively new dividend growth company. The company has decent growth prospects and is attractively valued. Investors should consider it for their dividend growth portfolio.

Amgen Is A Decent Addition To Your Dividend Growth Portfolio

VanEck Vectors Biotech ETF

Biogen

Gilead Sciences

iShares Nasdaq Biotechnology ETF

SPDR S&P Biotech ETF

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

How Are Biotech ETFs Reacting to These Q2 Earnings Releases?

Magellan Midstream Partners

Omega Healthcare Investors

Quality dividend-paying companies can be found in both bull and bear markets alike.

3 Great Dividends You May Kick Yourself For Not Buying Now

Archer-Daniels-Midland Company

Aflac

American States Water

Chevron

Emerson Electric

Honeywell

Eli Lilly

Microsoft

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

Upcoming Ex-Dividend Dates: July 6-July 19, 2021

News for Amgen Stock (AMGN)